AUTHORS
Antonio M. Risitano Jr, MD, PhD, Simona Iacobelli2, Austin G. Kulasekararaj, MD, MBBS, FRCPath, MRCP3, Marleen Van Os4, Joe Tuffnell5, Brian Piepenbroek6, Flore Sicre-de-Fontbrune, MD7, Camilla Frieri, MD, PhD8, Morag Griffin, FRCPath, MBChB, MRCP9, Constantijn Halkes10, Christian Recher11, Hélène Labussière-Wallet12, Edouard Forcade, MD, PhD13, Carlos Manuel Panizo Santos14, Beatrice Drexler15, Jean Baptiste Mear16, Roochi Trikha, PhD,FRPATH,MBChB,MRCP17, Laura Daenen18, Saskia Klein19, Etienne Daguindau20, Erfan Nur21, Bruno Fattizzo22, Louis Terriou, MD23, Anna Paola Iori24, Anna Maria Sureda Balari, MD,PhD25, Isabel Sanchez-Ortega I26, Juan Montoro, MD, PhD27, Tahla Munir, MBBS, FRCP, FRCPath, PhD28, Jennifer Tjon29, Marica Laurino30, Carlo Dufour I, MD31, Regis Peffault De Latour, MD, PhD32
AFFILIATIONS
1 AORN San Giuseppe Moscati, Avellino, Italy, European Society for Blood and Marrow Transplantation, Leiden, Netherlands, Federico II University, Naples, Italy
2 University of Rome Sapienza, Rome, Italy
3 European Society for Blood and Marrow Transplantation, Leiden, Netherlands, King's College Hospital NHS Foundation Trust, London, United Kingdom
4 European Society for Blood and Marrow Transplantation, Leiden, Netherlands
5 European Society for Blood and Marrow Transplantation, Leiden, Netherlands
6 European Society for Blood and Marrow Transplantation, Leiden, Netherlands
7 Saint-Louis Hospital and Université de Paris, Paris, France
8 AORN San Giuseppe Moscati, Avellino, Italy
9 St James's University Hospital, Leeds, United Kingdom
10 Leiden University Medical Center, Leiden, Netherlands
11 Centre Hospitalier Universitaire de Toulouse, Toulouse, France, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
12 helene.labussiere-wallet@chu-lyon.fr, Lyon, France
13 CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France
14 Hospital Universitario Donostia, San Sebastian, Spain
15 University of Basel, Basel, Switzerland
16 University Hospital of Rennes, Rennes, France
17 King's College Hospital NHS Foundation Trust, London, United Kingdom
18 University Medical Center Utrecht, Utrecht, Netherlands
19 University Medical Center Groningen, Groningen, Netherlands
20 CHU Besancon Franche-Comte, Besancon, France
21 Amsterdam University Medical Centers, Amsterdam, Netherlands
22 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, University of Milan, Milan, Italy
23 Hôpital Claude Huriez, Lille, France
24 Sapienza University, Rome, Italy
25 ICO Bellvitge-Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
26 European Society for Blood and Marrow Transplantation, Leiden, Netherlands
27 Hospital Universitario y Politécnico La Fe, Valencia, Spain
28 St James's University Hospital, Leeds, United Kingdom
29 Leiden University Medical Center, Leiden, Netherlands
30 IRCCS Ospedale Policlinico San Martino, Genoa, Italy
31 European Society for Blood and Marrow Transplantation, Leiden, Netherlands, IRCCS Istituto Giannina Gaslini, Genoa, Italy
32 European Society for Blood and Marrow Transplantation, Leiden, Netherlands, Saint-Louis Hospital and Université de Paris, Paris, France
ABSTRACT
Introduction
The RACE study (NCT02009747) compared standard Immuno-Suppressive Therapy (IST) (horse antithymocyte globulin plus ciclosporin A) with or without eltrombopag (EPAG, 150 mg/d from day +14 month 6 or or until month 3 in patients achieving an early complete response) as first-line treatment for Severe Aplastic Anemia (SAA). Analysis at 2-years showed that triple therapy improved the rate and quality of hematological response (primary endpoint 3-months complete response: 21.9% vs. 9.9%,), with improved 2-year overall survival (OS: 91% vs 86%), disease-free survival (DFS: 56% vs 37%) and event free-survival (EFS; 48% vs 32%). Here, we report the updated follow-up results of the extension phase of this trial.
Methods
Out of the 197 patients originally randomized in the RACE trial (arm A, standard IST: n=101; arm B, standard IST + EPAG: n=96), 170 completed the study as per protocol (22 deaths; 5 early termination due to consent withdrawal). At the end of the 2-year study period, all surviving RACE patients were offered enrollment in the extension, retrospective RACE-2 study, which collected long-term outcome information through the EBMT registry. Here we report long-term data on OS, DFS (events: death, no response at 6 months, myeloid malignancy, relapse, transplant), relapse (competing events: death, transplant or myeloid malignancy), evolution to myeloid malignancy (competing events: death and transplant) and secondary solid tumors (competing events: death).
Results
All 170 patients who completed the RACE trial qualified for enrollment in the RACE-2 study. The median follow-up for these patients was 81 months (range 24-123). We recorded 24 additional deaths during this long-term follow-up, leading to an OS rate of 80% in arm A and 76% in arm B (p=NS). In multivariate analysis (MVA), after adjustment for age and disease severity, treatment arm and disease severity were not associated with OS whereas age (>40y, HR 8.05, p=0.002) was an independent predictor of OS. The most common cause of death was the underlying disease (infectious or hemorrhagic complications) followed by transplant-related mortality, with no difference between treatment arms. With this longer follow-up, the number of patients undergoing a second-line hematopoietic stem cell transplantation were 22 in arm A and 21 in arm B, for a 5-year cumulative incidence (CI) of 21% and 20%, respectively (p=NS). The number of patients experiencing relapse was 14 in arm A and 28 in arm B, leading to a 5-year CI (assessed in responders only) of 29% and 37%, respectively (p=NS). In MVA, age was the only factor impacting the risk of relapse (>40y, HR 4.42; p<0.001). The risk of clonal evolution remained negligible, with 5 patients in each arm, leading to a 5-year CI of 3% in arm A and 6% in arm B (p=NS). These events resulted in a 5-year DFS of 30% in arm A and 43% in arm B (p=0.001), with this difference being mostly driven by the initial lack of response at 6 months. In MVA, treatment (arm B, HR 0.55; p<0.001), age (>40y, HR 1.93; p<0.001) and disease severity (very severe, HR 1.54; p=0.007) had all a statistically significant impact on DFS. We also observed 8 solid tumors (7 in arm A and 1 in arm B), corresponding to a 5-year CI of 6% in arm A and 1% in arm B (p=0.05); no recurrent cancer was observed (1 breast, 1 lung, 1 ovarian, 1 endometrium, 1 squamous cell carcinoma, 1 cutaneous epidermitis carcinoma, 1 unspecified, 1 melanoma,), nor dominance of solid cancers associated with constitutional disorders.
Conclusion
Extended follow-up of the RACE trial demonstrates that age is the major determinant of long-term outcome in patients with SAA, independently predicting both OS and relapse, while disease severity adversely impacts DFS. Despite similar excellent long-term overall survival between treatment arms, the durable DFS benefit achieved with upfront IST plus eltrombopag, without an increased risk of clonal myeloid evolution, confirms triple therapy as the standard of care for treatment-naïve severe aplastic anemia patients.
DISCLOSURES
Antonio M. Risitano Jr, MD, PhD: Alexion - Honoraria; Novartis - Honoraria; Sobi - Honoraria; Pfizer - Honoraria; Roche - Honoraria